25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CYP (Cynata) Stock Analysis
Buy, Hold or Sell?

Let's analyze Cynata together

I guess you are interested in Cynata Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Cynata’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Cynata’s Price Targets

I'm going to help you getting a better view of Cynata Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cynata Therapeutics Ltd

I send you an email if I find something interesting about Cynata Therapeutics Ltd.

1. Quick Overview

1.1. Quick analysis of Cynata (30 sec.)










1.2. What can you expect buying and holding a share of Cynata? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.03
Expected worth in 1 year
A$-0.14
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
A$-0.17
Return On Investment
-86.4%

For what price can you sell your share?

Current Price per Share
A$0.20
Expected price per share
A$0.145 - A$0.205
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cynata (5 min.)




Live pricePrice per Share (EOD)
A$0.20
Intrinsic Value Per Share
A$-0.56 - A$-0.35
Total Value Per Share
A$-0.53 - A$-0.31

2.2. Growth of Cynata (5 min.)




Is Cynata growing?

Current yearPrevious yearGrowGrow %
How rich?$4.6m$10.7m-$6.1m-131.9%

How much money is Cynata making?

Current yearPrevious yearGrowGrow %
Making money-$6.2m-$9.1m$2.9m46.5%
Net Profit Margin-420.8%-863.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Cynata (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#676 / 905

Most Revenue
#452 / 905

Most Profit
#426 / 905

Most Efficient
#640 / 905
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cynata?

Welcome investor! Cynata's management wants to use your money to grow the business. In return you get a share of Cynata.

First you should know what it really means to hold a share of Cynata. And how you can make/lose money.

Speculation

The Price per Share of Cynata is A$0.195. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cynata.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cynata, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.03. Based on the TTM, the Book Value Change Per Share is A$-0.04 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cynata.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.03-14.2%-0.03-14.2%-0.04-20.8%-0.03-14.3%-0.02-11.9%-0.02-9.8%
Usd Book Value Change Per Share-0.03-13.9%-0.03-13.9%-0.02-10.5%-0.02-10.3%0.00-1.1%0.00-0.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.03-13.9%-0.03-13.9%-0.02-10.5%-0.02-10.3%0.00-1.1%0.00-0.4%
Usd Price Per Share0.19-0.19-0.08-0.17-0.24-0.41-
Price to Earnings Ratio-6.84--6.84--1.98--7.92--15.29--27.80-
Price-to-Total Gains Ratio-7.00--7.00--3.91--9.78-0.84--43.99-
Price to Book Ratio9.24-9.24-1.69-4.77-5.31-11.42-
Price-to-Total Gains Ratio-7.00--7.00--3.91--9.78-0.84--43.99-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.125112
Number of shares7992
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.030.00
Usd Total Gains Per Share-0.030.00
Gains per Quarter (7992 shares)-215.96-17.04
Gains per Year (7992 shares)-863.82-68.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-864-8740-68-78
20-1728-17380-136-146
30-2591-26020-204-214
40-3455-34660-273-282
50-4319-43300-341-350
60-5183-51940-409-418
70-6047-60580-477-486
80-6911-69220-545-554
90-7774-77860-613-622
100-8638-86500-682-690

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.017.01.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%4.06.00.040.0%8.010.00.044.4%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.018.00.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%4.06.00.040.0%8.010.00.044.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Cynata Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.042-0.0420%-0.032-24%-0.031-26%-0.003-92%-0.001-97%
Book Value Per Share--0.0320.0320%0.074-57%0.071-55%0.082-61%0.067-52%
Current Ratio--5.5825.5820%7.460-25%7.456-25%11.896-53%13.260-58%
Debt To Asset Ratio--0.1400.1400%0.119+17%0.119+18%0.090+55%0.072+95%
Debt To Equity Ratio--0.1620.1620%0.135+20%0.135+20%0.101+61%0.079+105%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--71690793.00071690793.0000%42151321.000+70%72131885.333-1%101281838.800-29%154891352.900-54%
Eps---0.043-0.0430%-0.063+47%-0.043+1%-0.036-16%-0.030-31%
Ev To Ebitda Ratio---7.205-7.2050%-2.693-63%-8.999+25%-13.702+90%-25.372+252%
Ev To Sales Ratio--30.95930.9590%25.480+22%23.212+33%36.239-15%153.240-80%
Free Cash Flow Per Share---0.044-0.0440%-0.063+43%-0.041-8%-0.032-28%-0.026-42%
Free Cash Flow To Equity Per Share---0.044-0.0440%-0.033-24%-0.030-31%-0.001-98%0.000-10456%
Gross Profit Margin--1.0001.0000%1.0040%1.005-1%1.036-3%1.034-3%
Intrinsic Value_10Y_max---0.346----------
Intrinsic Value_10Y_min---0.561----------
Intrinsic Value_1Y_max---0.028----------
Intrinsic Value_1Y_min---0.045----------
Intrinsic Value_3Y_max---0.088----------
Intrinsic Value_3Y_min---0.146----------
Intrinsic Value_5Y_max---0.156----------
Intrinsic Value_5Y_min---0.257----------
Market Cap44061030.000-51%66656430.00066656430.0000%28244250.000+136%58748040.000+13%85636566.000-22%143480790.000-54%
Net Profit Margin---4.208-4.2080%-8.630+105%-4.513+7%-3.806-10%-4.892+16%
Operating Margin---4.418-4.4180%-9.630+118%-4.952+12%-4.321-2%-5.630+27%
Operating Ratio--4.9254.9250%10.000-51%5.271-7%4.637+6%5.949-17%
Pb Ratio6.105-51%9.2369.2360%1.688+447%4.773+94%5.310+74%11.422-19%
Pe Ratio-4.522+34%-6.840-6.8400%-1.978-71%-7.919+16%-15.294+124%-27.798+306%
Price Per Share0.195-51%0.2950.2950%0.125+136%0.260+13%0.379-22%0.635-54%
Price To Free Cash Flow Ratio-4.424+34%-6.692-6.6920%-1.978-70%-11.111+66%-19.224+187%-34.412+414%
Price To Total Gains Ratio-4.630+34%-7.004-7.0040%-3.908-44%-9.782+40%0.838-936%-43.990+528%
Quick Ratio--5.3965.3960%7.326-26%7.322-26%11.731-54%13.107-59%
Return On Assets---1.162-1.1620%-0.752-35%-0.706-39%-0.517-56%-0.483-58%
Return On Equity---1.350-1.3500%-0.853-37%-0.810-40%-0.584-57%-0.532-61%
Total Gains Per Share---0.042-0.0420%-0.032-24%-0.031-26%-0.003-92%-0.001-97%
Usd Book Value--4630577.9764630577.9760%10736201.410-57%10246523.307-55%11943391.443-61%9664490.029-52%
Usd Book Value Change Per Share---0.027-0.0270%-0.021-24%-0.020-26%-0.002-92%-0.001-97%
Usd Book Value Per Share--0.0200.0200%0.048-57%0.045-55%0.053-61%0.043-52%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--45996812.78945996812.7890%27044287.554+70%46279817.630-1%64982427.774-29%99378292.021-54%
Usd Eps---0.028-0.0280%-0.041+47%-0.028+1%-0.023-16%-0.019-31%
Usd Free Cash Flow---6390695.938-6390695.9380%-9163798.926+43%-5890234.678-8%-4631377.923-28%-3716010.796-42%
Usd Free Cash Flow Per Share---0.028-0.0280%-0.041+43%-0.026-8%-0.020-28%-0.016-42%
Usd Free Cash Flow To Equity Per Share---0.028-0.0280%-0.021-24%-0.020-31%-0.001-98%0.000-10456%
Usd Market Cap28269556.848-51%42766765.48842766765.4880%18121510.800+136%37692742.464+13%54944420.746-22%92057274.864-54%
Usd Price Per Share0.125-51%0.1890.1890%0.080+136%0.167+13%0.243-22%0.407-54%
Usd Profit---6252205.294-6252205.2940%-9160440.792+47%-6302089.481+1%-5234963.123-16%-4301255.796-31%
Usd Revenue--1485716.5491485716.5490%1061405.296+40%2510875.508-41%2604637.179-43%1675592.359-11%
Usd Total Gains Per Share---0.027-0.0270%-0.021-24%-0.020-26%-0.002-92%-0.001-97%
 EOD+3 -5MRQTTM+0 -0YOY+18 -203Y+12 -265Y+2 -3610Y+7 -31

3.3 Fundamental Score

Let's check the fundamental score of Cynata Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.522
Price to Book Ratio (EOD)Between0-16.105
Net Profit Margin (MRQ)Greater than0-4.208
Operating Margin (MRQ)Greater than0-4.418
Quick Ratio (MRQ)Greater than15.396
Current Ratio (MRQ)Greater than15.582
Debt to Asset Ratio (MRQ)Less than10.140
Debt to Equity Ratio (MRQ)Less than10.162
Return on Equity (MRQ)Greater than0.15-1.350
Return on Assets (MRQ)Greater than0.05-1.162
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Cynata Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.085
Ma 20Greater thanMa 500.188
Ma 50Greater thanMa 1000.214
Ma 100Greater thanMa 2000.217
OpenGreater thanClose0.195
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Cynata Therapeutics Ltd

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

Fundamental data was last updated by Penke on 2025-04-22 14:48:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Cynata earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Cynata to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -420.8%Β means thatΒ $-4.21 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cynata Therapeutics Ltd:

  • The MRQ is -420.8%. The company is making a huge loss. -2
  • The TTM is -420.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-420.8%TTM-420.8%0.0%
TTM-420.8%YOY-863.0%+442.2%
TTM-420.8%5Y-380.6%-40.2%
5Y-380.6%10Y-489.2%+108.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-420.8%-98.5%-322.3%
TTM-420.8%-185.9%-234.9%
YOY-863.0%-199.6%-663.4%
5Y-380.6%-357.6%-23.0%
10Y-489.2%-492.0%+2.8%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Cynata is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Cynata to theΒ Biotechnology industry mean.
  • -116.2% Return on Assets means thatΒ Cynata generatedΒ $-1.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cynata Therapeutics Ltd:

  • The MRQ is -116.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -116.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-116.2%TTM-116.2%0.0%
TTM-116.2%YOY-75.2%-41.0%
TTM-116.2%5Y-51.7%-64.5%
5Y-51.7%10Y-48.3%-3.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-116.2%-11.7%-104.5%
TTM-116.2%-12.0%-104.2%
YOY-75.2%-11.8%-63.4%
5Y-51.7%-12.8%-38.9%
10Y-48.3%-14.7%-33.6%
4.3.1.3. Return on Equity

Shows how efficient Cynata is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Cynata to theΒ Biotechnology industry mean.
  • -135.0% Return on Equity means Cynata generated $-1.35Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cynata Therapeutics Ltd:

  • The MRQ is -135.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -135.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-135.0%TTM-135.0%0.0%
TTM-135.0%YOY-85.3%-49.7%
TTM-135.0%5Y-58.4%-76.7%
5Y-58.4%10Y-53.2%-5.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-135.0%-15.5%-119.5%
TTM-135.0%-15.8%-119.2%
YOY-85.3%-15.5%-69.8%
5Y-58.4%-18.8%-39.6%
10Y-53.2%-21.3%-31.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Cynata Therapeutics Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Cynata is operatingΒ .

  • Measures how much profit Cynata makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Cynata to theΒ Biotechnology industry mean.
  • An Operating Margin of -441.8%Β means the company generated $-4.42 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cynata Therapeutics Ltd:

  • The MRQ is -441.8%. The company is operating very inefficient. -2
  • The TTM is -441.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-441.8%TTM-441.8%0.0%
TTM-441.8%YOY-963.0%+521.3%
TTM-441.8%5Y-432.1%-9.6%
5Y-432.1%10Y-563.0%+130.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-441.8%-187.2%-254.6%
TTM-441.8%-285.2%-156.6%
YOY-963.0%-209.8%-753.2%
5Y-432.1%-362.5%-69.6%
10Y-563.0%-470.7%-92.3%
4.3.2.2. Operating Ratio

Measures how efficient Cynata is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 4.92 means that the operating costs are $4.92 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 4.925. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.925. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.925TTM4.9250.000
TTM4.925YOY10.000-5.075
TTM4.9255Y4.637+0.288
5Y4.63710Y5.949-1.312
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9252.206+2.719
TTM4.9253.076+1.849
YOY10.0002.971+7.029
5Y4.6375.079-0.442
10Y5.9496.620-0.671
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Cynata Therapeutics Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cynata is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 5.58Β means the company has $5.58 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 5.582. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.582. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.582TTM5.5820.000
TTM5.582YOY7.460-1.878
TTM5.5825Y11.896-6.315
5Y11.89610Y13.260-1.363
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5823.658+1.924
TTM5.5823.926+1.656
YOY7.4604.286+3.174
5Y11.8965.793+6.103
10Y13.2606.182+7.078
4.4.3.2. Quick Ratio

Measures if Cynata is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Cynata to theΒ Biotechnology industry mean.
  • A Quick Ratio of 5.40Β means the company can pay off $5.40 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 5.396. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.396. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.396TTM5.3960.000
TTM5.396YOY7.326-1.931
TTM5.3965Y11.731-6.335
5Y11.73110Y13.107-1.376
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3962.909+2.487
TTM5.3963.439+1.957
YOY7.3264.158+3.168
5Y11.7315.834+5.897
10Y13.1076.519+6.588
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Cynata Therapeutics Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of CynataΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Cynata to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.14Β means that Cynata assets areΒ financed with 14.0% credit (debt) and the remaining percentage (100% - 14.0%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 0.140. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.140. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.140TTM0.1400.000
TTM0.140YOY0.119+0.021
TTM0.1405Y0.090+0.050
5Y0.09010Y0.072+0.018
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1400.340-0.200
TTM0.1400.340-0.200
YOY0.1190.331-0.212
5Y0.0900.357-0.267
10Y0.0720.382-0.310
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Cynata is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Cynata to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 16.2% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 0.162. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.162. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.162TTM0.1620.000
TTM0.162YOY0.135+0.027
TTM0.1625Y0.101+0.062
5Y0.10110Y0.079+0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1620.406-0.244
TTM0.1620.424-0.262
YOY0.1350.406-0.271
5Y0.1010.449-0.348
10Y0.0790.508-0.429
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Cynata generates.

  • Above 15 is considered overpriced butΒ always compareΒ Cynata to theΒ Biotechnology industry mean.
  • A PE ratio of -6.84 means the investor is paying $-6.84Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cynata Therapeutics Ltd:

  • The EOD is -4.522. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.840. Based on the earnings, the company is expensive. -2
  • The TTM is -6.840. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.522MRQ-6.840+2.319
MRQ-6.840TTM-6.8400.000
TTM-6.840YOY-1.978-4.862
TTM-6.8405Y-15.294+8.454
5Y-15.29410Y-27.798+12.503
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.522-1.826-2.696
MRQ-6.840-2.522-4.318
TTM-6.840-3.131-3.709
YOY-1.978-3.390+1.412
5Y-15.294-6.339-8.955
10Y-27.798-6.982-20.816
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cynata Therapeutics Ltd:

  • The EOD is -4.424. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.692. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.692. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.424MRQ-6.692+2.268
MRQ-6.692TTM-6.6920.000
TTM-6.692YOY-1.978-4.715
TTM-6.6925Y-19.224+12.532
5Y-19.22410Y-34.412+15.188
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.424-2.472-1.952
MRQ-6.692-3.474-3.218
TTM-6.692-4.066-2.626
YOY-1.978-4.356+2.378
5Y-19.224-8.499-10.725
10Y-34.412-9.639-24.773
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Cynata is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 9.24 means the investor is paying $9.24Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cynata Therapeutics Ltd:

  • The EOD is 6.105. Based on the equity, the company is overpriced. -1
  • The MRQ is 9.236. Based on the equity, the company is overpriced. -1
  • The TTM is 9.236. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.105MRQ9.236-3.131
MRQ9.236TTM9.2360.000
TTM9.236YOY1.688+7.548
TTM9.2365Y5.310+3.926
5Y5.31010Y11.422-6.113
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.1051.742+4.363
MRQ9.2362.283+6.953
TTM9.2362.457+6.779
YOY1.6882.529-0.841
5Y5.3103.754+1.556
10Y11.4224.307+7.115
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cynata Therapeutics Ltd.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Total Other Income Expense Net 4,363-2,9721,391-768622-12611-3,863-3,252



5.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets8,388
Total Liabilities1,171
Total Stockholder Equity7,217
 As reported
Total Liabilities 1,171
Total Stockholder Equity+ 7,217
Total Assets = 8,388

Assets

Total Assets8,388
Total Current Assets6,536
Long-term Assets1,852
Total Current Assets
Cash And Cash Equivalents 6,205
Net Receivables 113
Inventory -4
Other Current Assets 221
Total Current Assets  (as reported)6,536
Total Current Assets  (calculated)6,536
+/-0
Long-term Assets
Intangible Assets 1,852
Long-term Assets  (as reported)1,852
Long-term Assets  (calculated)1,852
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,171
Long-term Liabilities0
Total Stockholder Equity7,217
Total Current Liabilities
Accounts payable 432
Other Current Liabilities 739
Total Current Liabilities  (as reported)1,171
Total Current Liabilities  (calculated)1,171
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock81,625
Retained Earnings -82,319
Accumulated Other Comprehensive Income 7,911
Total Stockholder Equity (as reported)7,217
Total Stockholder Equity (calculated)7,217
+/-0
Other
Capital Stock81,625
Cash and Short Term Investments 6,205
Common Stock Shares Outstanding 179,632
Liabilities and Stockholders Equity 8,388
Net Debt -6,205
Net Invested Capital 7,217
Net Working Capital 5,365



5.3. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-30
> Total Assets 
3,557
2,328
1,420
1,249
1,218
1,017
1,793
9,926
9,125
9,031
14,254
16,133
12,250
17,481
29,975
26,548
18,994
8,388
8,38818,99426,54829,97517,48112,25016,13314,2549,0319,1259,9261,7931,0171,2181,2491,4202,3283,557
   > Total Current Assets 
3,489
2,181
1,224
972
1,207
1,017
1,150
5,104
4,751
4,937
10,441
12,600
7,330
13,851
27,282
24,135
16,861
6,536
6,53616,86124,13527,28213,8517,33012,60010,4414,9374,7515,1041,1501,0171,2079721,2242,1813,489
       Cash And Cash Equivalents 
3,248
2,079
1,005
628
389
993
1,117
5,095
4,704
4,879
10,350
12,206
6,977
13,650
26,717
23,798
16,167
6,205
6,20516,16723,79826,71713,6506,97712,20610,3504,8794,7045,0951,1179933896281,0052,0793,248
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
4
4
26
26
26
0
026262644000000000000
       Net Receivables 
133
102
219
344
510
24
33
10
48
55
88
53
63
17
278
100
367
113
113367100278176353885548103324510344219102133
       Inventory 
106
0
0
0
308
0
-33
-10
-48
-55
-88
-53
-63
0
0
0
0
-4
-40000-63-53-88-55-48-10-330308000106
       Other Current Assets 
2
2
83
161
421
0
33
10
48
58
55
338
286
184
287
237
327
221
221327237287184286338555848103304211618322
   > Long-term Assets 
68
146
196
277
11
0
643
4,822
4,374
4,093
3,813
3,533
4,919
3,630
2,693
2,413
2,133
1,852
1,8522,1332,4132,6933,6304,9193,5333,8134,0934,3744,82264301127719614668
       Property Plant Equipment 
9
7
2
20
11
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001120279
       Goodwill 
0
0
0
0
0
0
0
4,822
0
0
0
0
0
0
0
0
0
0
00000000004,8220000000
       Intangible Assets 
58
139
194
256
0
0
0
4,822
4,374
4,093
3,813
3,533
3,253
2,972
2,693
2,413
2,133
1,852
1,8522,1332,4132,6932,9723,2533,5333,8134,0934,3744,82200025619413958
       Long-term Assets Other 
0
0
0
0
0
0
-643
-4,822
-4,374
-4,093
-3,813
0
0
658
0
0
0
0
000065800-3,813-4,093-4,374-4,822-643000000
> Total Liabilities 
147
117
458
317
246
163
150
71
375
447
390
746
1,278
690
1,602
2,588
2,260
1,171
1,1712,2602,5881,6026901,27874639044737571150163246317458117147
   > Total Current Liabilities 
147
117
458
317
246
163
150
71
375
447
390
746
1,278
690
1,602
2,588
2,260
1,171
1,1712,2602,5881,6026901,27874639044737571150163246317458117147
       Short-term Debt 
0
0
0
0
20
0
0
0
33
0
0
0
0
0
0
0
0
0
00000000033000200000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
33
0
0
0
0
0
0
0
0
0
0000000003300000000
       Accounts payable 
63
20
10
60
134
17
14
35
153
134
95
299
791
297
676
1,580
1,309
432
4321,3091,5806762977912999513415335141713460102063
       Other Current Liabilities 
84
96
449
257
92
146
136
36
190
314
295
447
487
392
926
1,007
952
739
7399521,00792639248744729531419036136146922574499684
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
791
297
676
1,580
0
0
001,580676297791000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
3,533
3,253
2,972
2,693
2,413
2,133
0
02,1332,4132,6932,9723,2533,53300000000000
> Total Stockholder Equity
3,410
2,211
962
932
972
854
1,643
9,855
8,750
8,583
13,865
15,387
10,971
16,791
28,373
23,960
16,733
7,217
7,21716,73323,96028,37316,79110,97115,38713,8658,5838,7509,8551,6438549729329622,2113,410
   Common Stock
5,043
5,313
5,514
6,968
9,485
10,914
12,338
22,282
24,460
28,792
38,378
44,192
47,988
57,165
74,900
74,900
81,625
81,625
81,62581,62574,90074,90057,16547,98844,19238,37828,79224,46022,28212,33810,9149,4856,9685,5145,3135,043
   Retained Earnings -82,319-72,574-58,296-52,851-45,161-41,522-33,050-28,484-23,931-18,991-15,279-12,239-11,324-9,781-7,216-4,751-3,102-1,815
   Accumulated Other Comprehensive Income 
182
548
548
1,180
1,268
1,264
1,544
2,852
3,281
3,722
3,971
4,245
4,506
4,787
6,324
7,356
7,683
7,911
7,9117,6837,3566,3244,7874,5064,2453,9713,7223,2812,8521,5441,2641,2681,180548548182
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000



5.4. Balance Sheets

Currency in AUD. All numbers in thousands.




5.5. Cash Flows

Currency in AUD. All numbers in thousands.




5.6. Income Statements

Currency in AUD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue2,316
Cost of Revenue-281
Gross Profit2,3162,035
 
Operating Income (+$)
Gross Profit2,316
Operating Expense-11,124
Operating Income-8,808-8,808
 
Operating Expense (+$)
Research Development8,962
Selling General Administrative3,206
Selling And Marketing Expenses0
Operating Expense11,12412,168
 
Net Interest Income (+$)
Interest Income418
Interest Expense-0
Other Finance Cost-0
Net Interest Income418
 
Pretax Income (+$)
Operating Income-8,808
Net Interest Income418
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-12,060-5,555
EBIT - interestExpense = -10,230
-12,060
-9,745
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-10,230-12,060
Earnings Before Interest and Taxes (EBITDA)-9,950
 
After tax Income (+$)
Income Before Tax-12,060
Tax Provision-0
Net Income From Continuing Ops-9,745-12,060
Net Income-9,745
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses11,124
Total Other Income/Expenses Net-3,252-418
 

Technical Analysis of Cynata
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cynata. The general trend of Cynata is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cynata's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Cynata Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cynata Therapeutics Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.2 < 0.2 < 0.205.

The bearish price targets are: 0.15 > 0.15 > 0.145.

Know someone who trades $CYP? Share this with them.πŸ‘‡

Cynata Therapeutics Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cynata Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cynata Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cynata Therapeutics Ltd. The current macd is -0.00431055.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cynata price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cynata. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cynata price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cynata Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartCynata Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cynata Therapeutics Ltd. The current adx is 14.93.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cynata shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Cynata Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cynata Therapeutics Ltd. The current sar is 0.15743801.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cynata Therapeutics Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cynata Therapeutics Ltd. The current rsi is 49.08. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Cynata Therapeutics Ltd Daily Relative Strength Index (RSI) ChartCynata Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cynata Therapeutics Ltd. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cynata price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cynata Therapeutics Ltd Daily Stochastic Oscillator ChartCynata Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cynata Therapeutics Ltd. The current cci is 58.97.

Cynata Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartCynata Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cynata Therapeutics Ltd. The current cmo is 3.918726.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cynata Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartCynata Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cynata Therapeutics Ltd. The current willr is -8.33333333.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Cynata Therapeutics Ltd Daily Williams %R ChartCynata Therapeutics Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Cynata Therapeutics Ltd.

Cynata Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cynata Therapeutics Ltd. The current atr is 0.01176079.

Cynata Therapeutics Ltd Daily Average True Range (ATR) ChartCynata Therapeutics Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cynata Therapeutics Ltd. The current obv is -2,819,812.

Cynata Therapeutics Ltd Daily On-Balance Volume (OBV) ChartCynata Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cynata Therapeutics Ltd. The current mfi is 34.82.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cynata Therapeutics Ltd Daily Money Flow Index (MFI) ChartCynata Therapeutics Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cynata Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-31CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-02-10MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-27MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Cynata Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cynata Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.085
Ma 20Greater thanMa 500.188
Ma 50Greater thanMa 1000.214
Ma 100Greater thanMa 2000.217
OpenGreater thanClose0.195
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cynata with someone you think should read this too:
  • Are you bullish or bearish on Cynata? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cynata? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cynata Therapeutics Ltd

I send you an email if I find something interesting about Cynata Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Cynata Therapeutics Ltd.

Receive notifications about Cynata Therapeutics Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.